EURAND (NASDAQ:EURX)
12.63
0.03 (0.24%)
| EURAND (NASDAQ:EURX) Delayed : | |||||
|---|---|---|---|---|---|
| Previous Close | $12.66 | 52 Week High | $15.53 | ||
| Open | $12.63 | 52 Week Low | $6.17 | ||
| Day High | $12.75 | P/E | N/A | ||
| Day Low | $12.63 | EPS | $0.00 | ||
| Volume | 27,850 | ||||
| More EURX Info: Chart SEC Filings Profile Historical Options | |||||
What is this?Friends, Peers and Foes
| Ticker | # Stories | Ticker | # Stories |
|---|---|---|---|
| AKER | 1 | BLTI | 1 |
| CTCM | 1 | FTEK | 1 |
| HNR | 1 | KAMN | 1 |
| MEND | 1 | NXTM | 1 |
| REVU | 1 | SLRY | 1 |
| TRBN | 1 | XRM | 1 |
Entities who have mentioned EURX
- Thomas Weisel Partners Group | View Related Stories »
- Deutsche Bank | View Related Stories »
- Banc of America | View Related Stories »
- Merrill Lynch | View Related Stories »
- Cowen & Co | View Related Stories »
- 13G | View Related Stories »
- Barclays | View Related Stories »
- Initial Jobless Claims | View Related Stories »
- GLG Partners | View Related Stories »
- Trading Radar | View Related Stories »
- Life, Style and Real Estate | View Related Stories »
- Warburg Pincus | View Related Stories »
- Roth Capital | View Related Stories »
- Credit Suisse | View Related Stories »
- Carl Icahn | View Related Stories »
View All ReportsStreetInsider.com Reports on EURX
- Eurand (EURX) Announced Phase II/III Data for Pancreatic Enzyme Product ZENPEP
- Trading Radar for 11/05: Starbucks (SBUX), CBS Corp. (CBS), CVS (CVS), Toyota (TM), Thomson Reuters (TRI)
- Bank of America Initiates Coverage on Eurand N.V. (EURX) with a Neutral
- Deutsche Bank Raises Price Target on Eurand (EURX); WellPpositioned In Specialty Pharmaceutical Sector
- Roth Capital Initiates Coverage on Eurand NV (EURX) with a Buy
View All Press ReleasesCompany Press Releases on EURX
- Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Panc
- Eurand Reports Key Achievements and Strong Revenue Growth for Third Quarter 2009
- Eurand to Participate in Upcoming Investor Conferences
- Eurand Completes Public Offering, Including Exercise of the Underwriters' Over-Allotment Option, for Total Net Proceeds of Approximately $103.9 Million
- Eurand Announces Pricing of Offering of Ordinary Shares
StreetInsider Reports on EURX by Category
View All BlogsBlogs on EURX
- Eurand N.V. Q3 2009 Earnings Conference Call
- Analyst upgrades, downgrades and initiations: CMCSA, CS, JWN, RCL, RIMM, YUM ...
- FDA Approval Confirms Eurand's Long-Term Growth Potential
- Eurand N.V. Q2 2009 Earnings Call Transcript
- Analyst upgrades, downgrades and initiations: DELL, IBM, IPCR, NETL ...
View All FilingsSEC Filings on EURX
- Form 6-K EURAND N.V. For: Nov 13
- Form 6-K/A EURAND N.V. For: Sep 30
- Form SC 13G/A WARBURG PINCUS EQUITY
- Form 6-K EURAND N.V. For: Nov 04
- Form 6-K EURAND N.V. For: Oct 21
Comments on EURX
No comments are currently available.
